tradingkey.logo
tradingkey.logo
Search

FDA Reviews Corcept’s NDA for Relacorilant in Drug-Resistant Ovarian Cancer

ReutersSep 10, 2025 12:01 PM
facebooktwitterlinkedin

- Corcept Therapeutics Inc CORT.O:

  • FDA FILES CORCEPT’S NEW DRUG APPLICATION FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER

  • CORCEPT THERAPEUTICS INC - FDA ASSIGNS PDUFA DATE OF JULY 11, 2026 FOR RELACORILANT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI